The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Combinatorial biomarker expression in breast cancer
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 19×
“In HR? tumours, the mortality rate is appears constant overtime from diagnosis, whilst the rate for HR- tumours is high during the first 3–5 years and then declines showing a plateau curve of survival.”
BackgroundInfluentialSlamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“Following the development of a humanised monoclonal antibody against HER2 (trastuzumab; Herceptin; Genentech, South San Francisco, CA, USA) and clinical trials demonstrating benefit of the use of anti-HER2 agents in patients with HER2? BC [91–93], the reasons for establishing the HER2 status in routine clinical practi…”
BackgroundGene expression profiling predicts clinical outcome of breast cancer
van 't Veer, L. J., Dai, H., van de Vijver, M. J., He, Y. D., Hart, A. A. M., Mao, M., Peterse, H. L., van der Kooy, K., Marton, M. J., Witteveen, A. T., et al. (2002) · Nature · doi:10.1038/415530a · Cited by 9,536 · cited 2×
“Currently, several commercially available prognostic BC tests based on the expression of multiple genes (using transcriptome) are available, including Oncotype DX (21 genes; Genomic Health, Redwood City, California, USA) [13], MammaPrint (70 genes; Agendia BV, Amsterdam, the Netherlands) [14], Theros H/I (2 genes; Ava…”
MethodTrastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Overview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904
Harris, L. N., You, F., Schnitt, S. J., Witkiewicz, A., Lu, X., Sgroi, D., Ryan, P. D., Come, S. E., Burstein, H. J., Lesnikoski, B.-A., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1304 · Cited by 245
Cited by
Histological, molecular and functional subtypes of breast cancers
Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13879 · Cited by 475
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes
Dai, X., Xiang, L., Li, T., & Bai, Z. (2016) · Journal of Cancer · doi:10.7150/jca.13141 · Cited by 440
Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target
Filippou, P. S., Karagiannis, G. S., & Constantinidou, A. (2020) · Oncogene · doi:10.1038/s41388-019-1124-8 · Cited by 331
Eliyatkin, N., Yalcin, E., Zengel, B., Aktaş, S., & Vardar, E. (2015) · Journal of Breast Health · doi:10.5152/tjbh.2015.1669 · Cited by 317
Park, S., Koo, J. S., Kim, M. S., Park, H. S., Lee, J. S., Lee, J. S., Kim, S. I., & Park, B.-W. (2012) · The Breast · doi:10.1016/j.breast.2011.07.008 · Cited by 284
Metadata
- Authors
- Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2010-01-28
- Volume
- 120
- Issue
- 2
- Pages
- 293-308
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2063804661
- Cited by
- 219
- References
- 7
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.